OpenURL Connection Search - EBSCO

Connecting you to content on EBSCOhostUNIVERSITÄT DORTMUND

Select item for more details and to access through your institution.

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.
Published in:
Annals of Hematology, 2021, v. 100, n. 8, p. 2023, doi. 10.1007/s00277-020-04357-z
By:
- Mian, Afsar Ali;
- Haberbosch, Isabella;
- Khamaisie, Hazem;
- Agbarya, Abed;
- Pietsch, Larissa;
- Eshel, Elizabeh;
- Najib, Dally;
- Chiriches, Claudia;
- Ottmann, Oliver Gerhard;
- Hantschel, Oliver;
- Biondi, Ricardo M.;
- Ruthardt, Martin;
- Mahajna, Jamal
Publication type:
Article
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Published in:
2020
By:
- Janssen, Maike;
- Schäkel, Ulrike;
- Djuka Fokou, Carine;
- Krisam, Johannes;
- Stermann, Jacek;
- Kriegsmann, Katharina;
- Haberbosch, Isabella;
- Novotny, Jan Philipp;
- Weber, Stefan;
- Vehreschild, Maria;
- Bornhäuser, Martin;
- Bullinger, Lars;
- Schmitt, Michael;
- Liebregts, Tobias;
- Dreger, Peter;
- Lorenz, Hanns-Martin;
- Plaszczyca, Anna;
- Bartenschlager, Ralf;
- Müller, Barbara;
- Kräusslich, Hans-Georg
Publication type:
Letter